

PUBLISHER CORRECTION

Open Access



Publisher Correction: Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting

Liana Rizzi^{1,2} and Lea T. Grinberg^{1,3,4*}

Publisher Correction to: *acta neuropathol commun* 12, 36 (2024)

<https://doi.org/10.1186/s40478-024-01744-9>

Following the publication of the original article [1], it was noted that due to a typesetting error the figure legends were paired incorrectly. The figure legends for Figs. 1 and 2 were wrongly given as captions for Fig. 2, 1 respectively.

The publisher apologizes for the inconvenience caused.

The correct figures and captions have been included in this correction, and the original article [1] has been corrected.

The online version of the original article can be found at <https://doi.org/10.1186/s40478-024-01744-9>.

*Correspondence:

Lea T. Grinberg
lea.grinberg@ucsf.edu

¹Memory and Aging Center, Department of Neurology, Sandler Neurosciences Center, University of California San Francisco, 675 Nelson Rising Lane, 94158 San Francisco, CA, USA

²Department of Neurology, University of Campinas (UNICAMP), Campinas, SP, Brazil

³Department of Pathology, LIM-22, University of São Paulo Medical School, São Paulo, SP, Brazil

⁴Department of Pathology, University of California San Francisco, San Francisco, CA, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 1 Pathological mechanisms induced by caspase-cleaved tau



Fig. 2 Putative sites caspase-cleaved tau. Caspases 1, 3, 6, 7, and 8 cleave tau at D421. Caspase-2 cleaves tau also at D65 and D314, caspase-3 cleaves tau also at D25, caspase-6 cleaves tau also at D402 and D13. Tau consists of four domains: the projection domain (M1–Y197), a proline-rich region (P1 and P2), the microtubule-binding repeats (R1, R2, R3, R4), and a C-terminus domain (K369–L441). Amino acids 1–441

Published online: 12 April 2024

Alzheimer's disease: implications for biomarker development and therapeutic targeting. *acta Neuropathol Commun* 12:36. <https://doi.org/10.1186/s40478-024-01744-9>

References

1. Rizzi L, Grinberg LT (2024) Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.